Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts - PubMed (original) (raw)
. 2007 Nov 6;50(19):1884-93.
doi: 10.1016/j.jacc.2007.07.054. Epub 2007 Oct 23.
Affiliations
- PMID: 17980256
- DOI: 10.1016/j.jacc.2007.07.054
Free article
Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts
Oren Caspi et al. J Am Coll Cardiol. 2007.
Free article
Abstract
Objectives: We evaluated the ability of human embryonic stem cells (hESCs) and their cardiomyocyte derivatives (hESC-CMs) to engraft and improve myocardial performance in the rat chronic infarction model.
Background: Cell therapy is emerging as a novel therapy for myocardial repair but is hampered by the lack of sources for human cardiomyocytes.
Methods: Immunosuppressed healthy and infarcted (7 to 10 days after coronary ligation) rat hearts were randomized to injection of undifferentiated hESCs, hESC-CMs, noncardiomyocyte hESC derivatives, or saline. Detailed histological analysis and sequential echocardiography were used to determine the structural and functional consequences of cell grafting.
Results: Transplantation of undifferentiated hESCs resulted in the formation of teratoma-like structures. This phenomenon was prevented by grafting of ex vivo pre-differentiated hESC-CMs. The grafted cardiomyocytes survived, proliferated, matured, aligned, and formed gap junctions with host cardiac tissue. Functionally, animals injected with saline or nonmyocyte hESC derivatives demonstrated significant left ventricular (LV) dilatation and functional deterioration, whereas grafting of hESC-CMs attenuated this remodeling process. Hence, post-injury baseline fractional shortening deteriorated by 50% (from 20 +/- 2% to 10 +/- 2%) and by 30% (20 +/- 2% to 14 +/- 2%) in the saline and nonmyocyte groups while improving by 22% (21 +/- 2% to 25 +/- 3%) in the hESC-CM group. Similarly, wall motion score index and LV diastolic dimensions were significantly lower in the hESC-CM animals.
Conclusions: Transplantation of hESC-CMs after extensive myocardial infarction in rats results in the formation of stable cardiomyocyte grafts, attenuation of the remodeling process, and functional benefit. These findings highlight the potential of hESCs for myocardial cell therapy strategies.
Comment in
- Human stem cells for heart failure treatment ready for prime time?
Condorelli G, Catalucci D. Condorelli G, et al. J Am Coll Cardiol. 2007 Nov 6;50(19):1894-5. doi: 10.1016/j.jacc.2007.07.057. Epub 2007 Oct 23. J Am Coll Cardiol. 2007. PMID: 17980257 No abstract available.
Similar articles
- Transplantation of embryonic stem cell-derived cardiomyocytes improves cardiac function in infarcted rat hearts.
Cai J, Yi FF, Yang XC, Lin GS, Jiang H, Wang T, Xia Z. Cai J, et al. Cytotherapy. 2007;9(3):283-91. doi: 10.1080/14653240701247838. Cytotherapy. 2007. PMID: 17464760 - Human stem cells for heart failure treatment ready for prime time?
Condorelli G, Catalucci D. Condorelli G, et al. J Am Coll Cardiol. 2007 Nov 6;50(19):1894-5. doi: 10.1016/j.jacc.2007.07.057. Epub 2007 Oct 23. J Am Coll Cardiol. 2007. PMID: 17980257 No abstract available. - A combined cell therapy and in-situ tissue-engineering approach for myocardial repair.
Habib M, Shapira-Schweitzer K, Caspi O, Gepstein A, Arbel G, Aronson D, Seliktar D, Gepstein L. Habib M, et al. Biomaterials. 2011 Oct;32(30):7514-23. doi: 10.1016/j.biomaterials.2011.06.049. Epub 2011 Jul 23. Biomaterials. 2011. PMID: 21783246 - Stem cells in cardiac repair.
Henning RJ. Henning RJ. Future Cardiol. 2011 Jan;7(1):99-117. doi: 10.2217/fca.10.109. Future Cardiol. 2011. PMID: 21174514 Review. - Cardiovascular therapeutic aspects of cell therapy and stem cells.
Gepstein L. Gepstein L. Ann N Y Acad Sci. 2006 Oct;1080:415-25. doi: 10.1196/annals.1380.030. Ann N Y Acad Sci. 2006. PMID: 17132798 Review.
Cited by
- Pluripotent stem cells for cardiac regeneration: overview of recent advances & emerging trends.
Pawani H, Bhartiya D. Pawani H, et al. Indian J Med Res. 2013 Feb;137(2):270-82. Indian J Med Res. 2013. PMID: 23563370 Free PMC article. Review. - Striated muscle function, regeneration, and repair.
Shadrin IY, Khodabukus A, Bursac N. Shadrin IY, et al. Cell Mol Life Sci. 2016 Nov;73(22):4175-4202. doi: 10.1007/s00018-016-2285-z. Epub 2016 Jun 6. Cell Mol Life Sci. 2016. PMID: 27271751 Free PMC article. Review. - Healing the Ischaemic Heart: A Critical Review of Stem Cell Therapies.
Tonkin D, Yee-Goh A, Katare R. Tonkin D, et al. Rev Cardiovasc Med. 2023 Apr 19;24(4):122. doi: 10.31083/j.rcm2404122. eCollection 2023 Apr. Rev Cardiovasc Med. 2023. PMID: 39076280 Free PMC article. Review. - Multipotency and cardiomyogenic potential of human adipose-derived stem cells from epicardium, pericardium, and omentum.
Wystrychowski W, Patlolla B, Zhuge Y, Neofytou E, Robbins RC, Beygui RE. Wystrychowski W, et al. Stem Cell Res Ther. 2016 Jun 13;7(1):84. doi: 10.1186/s13287-016-0343-y. Stem Cell Res Ther. 2016. PMID: 27296220 Free PMC article. - Stem cell-derived cardiomyocytes expressing a dominant negative pacemaker HCN4 channel do not reduce the risk of graft-related arrhythmias.
Wulkan F, Romagnuolo R, Qiang B, Valdman Sadikov T, Kim KP, Quesnel E, Jiang W, Andharia N, Weyers JJ, Ghugre NR, Ozcan B, Alibhai FJ, Laflamme MA. Wulkan F, et al. Front Cardiovasc Med. 2024 Jul 9;11:1374881. doi: 10.3389/fcvm.2024.1374881. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39045008 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous